Mandate

Vinge advises Doro in connection with the acquisition of IVS

May 15, 2013

Vinge has advised Doro in connection with the acquisition of the German distributor IVS Industrievertretung Schweiger GmbH (“IVS”). The acquisition price for IVS, including the maximum additional purchase price in 2014 and 2015, amounts to EUR 17.6 million on a cash and debt free basis. The acquisition is financed through a combination of existing cash and bank loans and Doro also has an option to finance part of the acquisition with Doro shares.

Doro’s products and solutions are available in more than 30 countries spanning five continents and the product range includes mobile phones, apps and software, fixed telephony, telecare and solutions within mHealth. Doro’s turnover in 2012 was SEK 837.5 million and the company’s shares are listed on OMX Nasdaq Stockholm, Nordic List, Small-cap.

Vinge primarily advised Doro on the capital markets and corporate law issues pertaining to the acquisition. Vinge’s team consisted of responsible partner Johan Winnerblad together with associates Charlotte Levin, Matthias Pannier, Dain Nevonen and Christian Hybbinette. 

Related

Vinge advises Intera Partners’ portfolio company Yellow Elk in connection with its acquisition of Bizware

Vinge has advised the Nordic private equity firm Intera Partners’ portfolio company Yellow Elk in connection with its acquisition of the data analytics and AI firm Bizware AB and its subsidiaries Bizware Lead AB and Bizware Nova AB.
September 11, 2025

Vinge has acted as local counsel supporting lead counsel Latham & Watkins in advising Cadence in connection with its acquisition of Hexagon’s Design & Engineering Business for approx. EUR 2.7 billion

Cadence (Nasdaq: CDNS) announced it has entered into a definitive agreement to acquire the Design & Engineering business of Hexagon AB, which includes its MSC Software business—a pioneer in engineering simulation and analysis solutions.
September 09, 2025

Vinge has advised Oncopeptides in connection with its rights issue

Vinge has advised Oncopeptides AB (publ) in connection with a fully guaranteed rights issue which will provide Oncopeptides with proceeds of approximately SEK 150 million before deduction of transaction costs.
August 28, 2025